Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Aug 28:10:2060.
doi: 10.3389/fimmu.2019.02060. eCollection 2019.

Immunotherapy in People With HIV and Cancer

Camille E Puronen  1 , Emily S Ford  2   3 , Thomas S Uldrick  1   3   4
Affiliations
Review

Immunotherapy in People With HIV and Cancer

Camille E Puronen et al. Front Immunol. .

Abstract

HIV infection alters the natural history of several cancers, in large part due to its effect on the immune system. Immune function in people living with HIV may vary from normal to highly dysfunctional and is largely dependent on the timing of initiation (and continuation) of effective antiretroviral therapy (ART). An individual's level of immune function in turn affects their cancer risk, management, and outcomes. HIV-associated lymphocytopenia and immune dysregulation permit immune evasion of oncogenic viruses and premalignant lesions and are associated with inferior outcomes in people with established cancers. Various types of immunotherapy, including monoclonal antibodies, interferon, cytokines, immunomodulatory drugs, allogeneic hematopoietic stem cell transplant, and most importantly ART have shown efficacy in HIV-related cancer. Emerging data suggest that checkpoint inhibitors targeting the PD-1/PD-L1 pathway can be safe and effective in people with HIV and cancer. Furthermore, some cancer immunotherapies may also affect HIV persistence by influencing HIV latency and HIV-specific immunity. Studying immunotherapy in people with HIV and cancer will advance clinical care of all people living with HIV and presents a unique opportunity to gain insight into mechanisms for HIV eradication.

Keywords: HIV; HIV reservoir; Kaposi sarcoma; PD-1; cancer; immunotherapy; lymphoma.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Immunotherapy and the HIV reservoir. A variety of immunotherapeutic agents used to treat cancer may perturb the HIV reservoir through induction of latency reversal or increased cell killing. Some of these agents are being evaluated in clinical trials targeting HIV persistence. CPI, immune checkpoint inhibitor; IL, interleukin.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Coghill AE, Han X, Suneja G, Lin CC, Jemal A, Shiels MS. Advanced stage at diagnosis and elevated mortality among US patients with cancer infected with HIV in the National Cancer Data Base. Cancer. (2019) 125:2868–76. 10.1002/cncr.32158 - DOI - PMC - PubMed
    1. Shepherd L, Ryom L, Law M, Petoumenos K, Hatleberg CI, d'Arminio Monforte A, et al. . Cessation of cigarette smoking and the impact on cancer incidence in human immunodeficiency virus-infected persons: the data collection on adverse events of anti-HIV drugs study. Clin Infect Dis. (2019) 68:650–7. 10.1093/cid/ciy508 - DOI - PubMed
    1. Grover S, Desir F, Jing Y, Bhatia RK, Trifiletti DM, Swisher-McClure S, et al. . Reduced cancer survival among adults with HIV and AIDS-defining illnesses despite no difference in cancer stage at diagnosis. J Acquir Immune Defic Syndr. (2018) 79:421–9. 10.1097/QAI.0000000000001842 - DOI - PMC - PubMed
    1. Hernandez-Ramirez RU, Qin L, Lin H, Leyden W, Neugebauer RS, Althoff KN, et al. Association of immunosuppression and HIV viremia with anal cancer risk in persons living with HIV in the United States and Canada. Clin Infect Dis. (2019) 2019:ciz329 10.1093/cid/ciz329 - DOI - PMC - PubMed
    1. Hernández-Ramírez RU, Qin L, Lin H, Leyden W, Neugebauer RS, Althoff KN, et al. . Association of immunosuppression and HIV viraemia with non-Hodgkin lymphoma risk overall and by subtype in people living with HIV in Canada and the USA: a multicentre cohort study. Lancet HIV. (2019) 6:e240–e9. - PMC - PubMed

Publication types

Substances